Takeda resubmits alogliptin NDAs in US as cardiovascular data become available
This article was originally published in Scrip
Executive Summary
Takeda has resubmitted to the US FDA two NDAs for products containing its DPP-4 inhibitor alogliptin, following a substantial delay caused by the need to conduct a cardiovascular safety study.